The abstract is read at the publisher; the summary is JClub's.
FDA approval of daraxonrasib (Rasonque) for adults with metastatic pancreatic ductal adenocarcinoma after prior therapy marks a direct RAS-targeting breakthrough.
- Why it matters: Pancreatic ductal adenocarcinoma has been a therapeutic “drug graveyard,” with limited benefit from cytotoxic combinations and many novel agents failing in trials.
- What they did: The authors review a wave of clinical trials, emphasizing RAS-targeted approaches that have advanced to phase 3, to assess emerging strategies for PDAC.
- The result: These phase 3 studies suggest RAS-targeted therapies could reshape the PDAC treatment landscape and determine whether they yield durable survival gains.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.